From: Unmet needs about iron deficiency in peritoneal dialysis: a Delphi consensus panel
Statement 16 | |||||
Referring to the use of I.V. iron and to the costs optimization for the treatment of anaemia in the patient in peritoneal dialysis, I retain: | 1 | 2 | 3 | 4 | 5 |
16.1 That an evaluation should be performed | 8% | 92% | |||
2 | 0 | 5 | 13 | 5 | |
16.2 That the use of ferric carboxymaltose let a reduction of the use of ESA which is able to overrule the greater cost of the drug itself | 8% | 92% | |||
0 | 2 | 3 | 9 | 11 | |
16.3 To observe an improvement in clinical outcomes but not in the use of ESA | 32% | 68% | |||
1 | 7 | 10 | 5 | 2 | |
16.4 That the hospital pharmacy does not consent the use of iron molecules at a higher cost | 68% | 32% | |||
5 | 12 | 4 | 4 | 0 | |
16.5 That pharmacoeconomic data now available do not let to clearly highlight an advantage among different molecules | 52% | 48% | |||
4 | 9 | 7 | 3 | 2 |